Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	673	560	434	363.33	351.41
Revenue Growth (YoY)	20.18%	29.03%	19.45%	3.39%	29.66%
Cost of Revenue	109	77	45	28.32	16.01
Gross Profit	564	483	389	335.01	335.4
Selling, General & Admin	349	321	310	278.14	219.98
Research & Development	750	698	648	705.79	497.15
Total Operating Expenses	1,099	1,019	958	983.93	717.14
Operating Income	-535	-536	-569	-648.92	-381.74
Interest Income	25	37	27	11.07	1.93
Interest Expense	-62	-63	-66	-43.02	-29.42
Other Non-Operating Income (Expense)	1	-5	-1	-20.87	-43.75
Total Non-Operating Income (Expense)	-36	-31	-40	-52.81	-71.24
Pretax Income	-571	-567	-609	-701.73	-452.98
Provision for Income Taxes	4	2	-2	5.7	1.04
Net Income	-575	-569	-607	-707.42	-454.03
Net Income to Common	-575	-569	-607	-707.42	-454.03
Shares Outstanding (Basic)	99	91	74	70	68
Shares Outstanding (Diluted)	99	91	74	70	68
Shares Change (YoY)	8.95%	23.13%	5.13%	3.13%	11.42%
EPS (Basic)	-5.83	-6.29	-8.25	-10.12	-6.70
EPS (Diluted)	-5.83	-6.29	-8.25	-10.12	-6.70
Free Cash Flow	-472	-421	-519	-496.59	-411.79
Free Cash Flow Per Share	-4.79	-4.65	-7.06	-7.10	-6.07
Gross Margin	83.80%	86.25%	89.63%	92.21%	95.44%
Operating Margin	-79.49%	-95.71%	-131.11%	-178.60%	-108.63%
Profit Margin	-85.44%	-101.61%	-139.86%	-194.71%	-129.20%
FCF Margin	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%
EBITDA	-500	-500	-543	-630.7	-368.5
EBITDA Margin	-74.29%	-89.29%	-125.12%	-173.59%	-104.86%
EBIT	-535	-536	-569	-648.92	-381.74
EBIT Margin	-79.49%	-95.71%	-131.11%	-178.60%	-108.63%
Effective Tax Rate	-0.70%	-0.35%	0.33%	-0.81%	-0.23%

Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q